• Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
Search
Arvinas Logo
Arvinas logo
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
Search
  • Our Science
    • Overview
    • PROTAC Discovery Engine
    • Publications
    • Congress Presentations
    • Partnerships
  • Pipeline and R&D
    • Overview
    • Pipeline
  • About Us
    • Overview
    • Executive Committee
    • Board of Directors
    • Scientific Advisory Board
  • Patients
    • Overview
    • Clinical Trials
    • Expanded Access Policy
  • Careers and Culture
    • Life at Arvinas
    • Join Us
  • Investors and Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Corporate Governance
    • Financials and SEC Filings
    • Annual Meeting
    • Stock Information
    • Analyst Coverage
    • Investor FAQs
    • Resources
    • Email Alerts
  • Contact Us
13SepSeptember 13, 2023

ISSX 2023

10SepSeptember 10, 2023

In Vitro Evaluation of PROTAC® Androgen Receptor Degrader ARV-766 for Cytochrome P450- and Transporter-Mediated Drug-Drug Interaction

27AugAugust 27, 2023

MDS 2023

27AugAugust 27, 2023

Development of Potent, Orally Bioavailable, and Highly Selective LRRK2 PROTAC® Degrader Molecules as Potential Disease Modifying Therapeutics for Parkinson’s Disease

27AugAugust 27, 2023

LRRK2 PROTAC® Degrader Molecules Induce Robust Biomarker Responses in Preclinical In Vivo Pharmacology Studies Following Acute and Chronic Oral Dosing

26MayMay 26, 2023

ACS Spring 2023

25AprApril 25, 2023

CSHL Ubiquitins, Autophagy & Disease 2023

25AprApril 25, 2023

Small Molecule PROTAC® Hijacking and Structural Characterization of an E3 Ligase, KLHDC2, for Targeted Protein Degradation

14AprApril 14, 2023

AACR 2023

14AprApril 14, 2023

Discovery of ARV-766, an Androgen Receptor Degrading PROTAC® for the Treatment of Men with Metastatic Castration Resistant Prostate Cancer

  Prev1…456Next  
Arvinas logo
  • Careers
  • Privacy Policy
  • Terms of Use
LinkedIn
X

Accessibility Statement

© 2026 Arvinas. All rights reserved.

Arvinas

You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE